Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial

IMPORTANCE: The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival. The Three or Six Colon Adjuvant (TOSCA) trial compared 3 months with 6 months...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA Oncol
Main Authors: Petrelli, Fausto, Labianca, Roberto, Zaniboni, Alberto, Lonardi, Sara, Galli, Fabio, Rulli, Eliana, Rosati, Gerardo, Corallo, Salvatore, Ronzoni, Monica, Cardellino, Giovanni Gerardo, Mattioli, Rodolfo, Mambrini, Andrea, Ciuffreda, Libero, Banzi, Maria, Pusceddu, Valeria, Maiello, Evaristo, Zampino, Maria, Zagonel, Vittorina, Marchetti, Paolo, Corsi, Domenico, Rimassa, Lorenza, Cinieri, Saverio, Sobrero, Alberto
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2020
נושאים:
Brief Report
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042800/
https://ncbi.nlm.nih.gov/pubmed/32053133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.6486
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים